Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > PRC Partners (June 2022)

<< Previous

Bullboard Posts

Next >>

Comment by forhandlarenon Feb 27, 2024 3:48pm

100 Views

Post# 35902264

RE:RE:RE:RE:RE:PRC Partners (June 2022)

You forget the R+F product that was sold to consumers, but Sirona choose to abort the deal in favour of Abbvie.

The usual period of time between contract and product launch is 18 months. I suggest you contact management and return to this Bullboard with the insight you gained regarding to product launch.

PRC was kicked out by management for misleading the market. You should know that since you claim 16 years of company experience.

Try to stick with verified facts next post.

Thanks

<< Previous

Bullboard Posts

Next >>

E3 inches closer to Alberta's first lithium production plant